TQH-2722 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Rhinosinusitis. According to GlobalData, Phase II drugs for Rhinosinusitis have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TQH-2722’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TQH-2722 overview

TQH-2722 is under development for the treatment of moderate to severe atopic dermatitis and chronic rhinosinusitis with nasal poly. The drug candidate acts by targeting interleukin 4 receptor subunit alpha (IL4R). The drug candidate is administered by subcutaneous route.

Chia Tai Tianqing Pharmaceutical Group overview

Chia Tai Tianqing Pharmaceutical Group (CTTQ) subsidiary of Sino Biopharmaceutical Ltd, is a pharmaceutical company that offers integrated R&D, manufacturing, marketing, sales and distribution services. The company manufacture prescription medicines in various core therapeutic areas, including liver diseases, oncology, respiratory diseases, antibiotics and diabetes. CTTQ produces dosage forms such as freeze-dried powder, large and small volume injections, hard capsules, sheet pills, granules, powders, soft capsules, pills, ointments, creams, pastes, gels, transdermal patches and herbal extracts, and others. It conducts research activities in the areas of anti-tumor, and liver disease. The company operates through its technology and research and development centers in Jiangsu. Its APIs and FDFs are sold to all major continents including Americas, Europe, Asia, and Africa. CTTQ is headquartered in Lianyungang, Nanjing, China.

For a complete picture of TQH-2722’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.